Statement Of Cash Flows [Abstract]

ABIONYX Pharma - Filing #879713

Concept 2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for interest expense
1,000 EUR
1,000 EUR
Cash flows from (used in) operations before changes in working capital
4 948 EUR
2 729 EUR
Increase (decrease) in working capital
1 744 EUR
2 130 EUR
Adjustments for decrease (increase) in loans and advances
Adjustments for decrease (increase) in loans and advances to banks
900,000 EUR
Adjustments for amortisation expense
119,000 EUR
22,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.